Biological therapy for rheumatoid arthritis: where are we now?

Br J Hosp Med (Lond). 2012 Jan;73(1):12-8. doi: 10.12968/hmed.2012.73.1.12.

Abstract

Since the introduction of targeted biological therapies, the implications of a new diagnosis of rheumatoid arthritis have changed dramatically. There are now several therapeutic options available for these patients and the target of treatment - remission - is now a realistic goal.

Publication types

  • Review

MeSH terms

  • Abatacept
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Antirheumatic Agents / administration & dosage
  • Antirheumatic Agents / adverse effects
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • Humans
  • Immunoconjugates / therapeutic use
  • Immunotherapy*
  • Methotrexate / therapeutic use
  • Molecular Targeted Therapy
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Remission Induction
  • Rituximab
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antirheumatic Agents
  • Immunoconjugates
  • Tumor Necrosis Factor-alpha
  • Rituximab
  • Abatacept
  • tocilizumab
  • Methotrexate